Corrigendum

Abstract

Cancer MedicineVolume 10, Issue 7 p. 2526-2527 CORRIGENDUMOpen Access Corrigendum This article corrects the following: Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells Chao Liu, Qianqian Liu, Aiwen Yan, Hui Chang, Yuyin Ding, Junye Tao, Chen Qiao, Volume 9Issue 11Cancer Medicine pages: 3875-3884 First Published online: April 5, 2020 First published: 02 March 2021 https://doi.org/10.1002/cam4.3702AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat In the article by Chao Liu et al., the corresponding author would like to include the affiliation for Qianqian Liu in author byline and also add the authors contribution line. The included affiliation and authors contribution line should read as follows: Metformin Revert Insulin-induced Oxaliplatin Resistance by Activating Mitochondrial Apoptosis Pathway in Human Colon cancer HCT116 Cells Chao Liu1,#, Qianqian Liu2,#, Aiwen Yan1, Hui Chang1, Yuyin Ding1, Junye Tao1, Chen Qiao1,* 1Department of Pharmacy, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, China 2China Pharmaceutical University, School of Basic Medicine and Clinical Pharmacy, Nanjing, 211198, China #Chao Liu and Qianqian Liu are contributed equally to this work. The authors have also noticed an error that the western blot band was misplaced in Figure 4. The correct version of the Figure 4 is displayed below. FIGURE 4 Metformin inhibit Bcl-2 expression via AMPK activation. A-C, HCT116 cells were incubated with 20 nmol/L 12 wks of insulin stimulation with metformin (5 mmol/L) combination as described, then AMPK inhibitor compound C, AMPK siRNA, and LY3214996 were applied as described. Then AMPK, ERK, and Bcl-2 expression were analyzed by immunoblot. D-E, HCT116 cells were stained with Annexin V and PI and apoptosis cells were quantitated by flow cytometer after chronic insulin treatment combined with metformin (5 mmol/L), then AMPK inhibitor compound C, AMPK siRNA, and LY3214996 were applied as described. Bars represent SEM, ***P < .005 vs chronic insulin + metformin-treated HCT116 cells The authors apologize for this error. REFERENCE 1Liu C, Liu Q, Yan A, et al. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells. Cancer Med. 2020; 9: 3875– 3884. https://doi.org/10.1002/cam4.3029Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Volume10, Issue7April 2021Pages 2526-2527 ReferencesRelatedInformation